AUSTRALIAN-LISTED digital medication adherence company MedAdvisor has announced via the ASX that it has signed the Australian branch of the world's largest pharmaceutical company, Pfizer, to provide a Patient Engagement Program (PEP) for one of its leading medications.
The MedAdvisor platform will be used to deliver important information and guidance to patients prescribed the medication for an initial 18 month period.
Content will include a series of educational communications that aims to improve the patient's quality use of medicines, in turn delivering better patient outcomes.
MedAdvisor has said that it will receive PEP revenue from Pfizer for the duration of the contract, further growing its PEP revenue stream.
Pfizer is the ninth pharmaceutical company to contract with MedAdvisor, with two of the current contracts recently extended for a further 12 months.
The above article was sent to subscribers in Pharmacy Daily's issue from 09 Dec 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Dec 16
